<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-10-04-2026-image1-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-10-04-2026-image1-430x241.jpg"/></p>
<p>根據協議，JW Pharmaceutical 獲得在韓國開發和商業化 bofanglutide 的獨佔權。來源：Gan &amp; Lee Pharmaceuticals / PR Newswire。</p>
<p>Gan &amp; Lee Pharmaceuticals 與 JW Pharmaceutical 簽署了獨佔許可協議，涉及在韓國進行 bofanglutide 注射的臨牀開發、監管審批和商業化。</p>
<p>Bofanglutide 是由 Gan &amp; Lee 發現和開發的雙週給藥的類胰高血糖素肽-1 受體激動劑 (GLP-1RA)。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>LOA 和 PTSR 模型 - (LAI-287 + semaglutide) 在 2 型糖尿病中的應用</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>LOA 和 PTSR 模型 - CT-868 在肥胖症中的應用</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現高效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>根據協議，JW Pharmaceutical 獲得開發和商業化該注射劑的獨佔權。</p>
<p>Gan &amp; Lee 將利用 JW Pharmaceutical 在研發方面的優勢，在韓國的代謝疾病市場建立商業存在。</p>
<p>Gan &amp; Lee 將獲得 500 萬美元的不可退還預付款，以及高達 7610 萬美元的里程碑付款，具體取決於研究、監管和商業化目標。</p>
<p>該公司還將獲得淨銷售額的分級版税，使交易的總潛在價值達到 8110 萬美元，不包括版税。</p>
<p>這是 Bofanglutide 的第三個海外授權交易，此前在印度和拉丁美洲也簽署了類似協議。</p>
<p>Bofanglutide 已進入 III 期臨牀研究，針對肥胖/超重、2 型糖尿病和阻塞性睡眠呼吸暫停等適應症。</p>
<p>數據顯示，該注射劑能夠降低體重和血糖水平，同時對代謝參數產生有利影響，其安全性和耐受性與其他 GLP-1RA 療法相似。</p>
<p>雙週給藥的方案將年注射次數減少了一半，相較於標準的每週一次的替代方案。</p>
<p>Gan &amp; Lee Pharmaceuticals 首席商務官 Dr Zhi Li 表示：“與 JW Pharmaceutical 的合作標誌着 bofanglutide 全球化戰略的又一個關鍵步驟。GLP-1 療法正在重塑代謝疾病的全球治療格局。</p>
<p>“Bofanglutide 雙週給藥的便利性及其顯著的臨牀益處將有助於滿足韓國患者未被滿足的醫療需求。JW 擁有超過 80 年的經驗，在代謝疾病領域具備深厚的開發和商業專業知識，這是我們選擇與 JW 合作的關鍵因素。”</p>

甘李藥業

<p>甘李藥業已與 JW Pharmaceutical 簽署獨家許可協議，以在韓國商業化博方魯肽注射液。JW Pharmaceutical 將開發和商業化該藥物，獲得 500 萬美元的預付款以及總計 7610 萬美元的潛在里程碑付款。博方魯肽是一種每兩週一次的 GLP-1 受體激動劑，目前正在進行針對肥胖、2 型糖尿病和睡眠呼吸暫停的第三階段臨牀試驗。此次合作旨在利用 JW 在代謝疾病市場的專業知識，提升韓國的患者護理</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-10-04-2026-image1-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-10-04-2026-image1-430x241.jpg"/></p>
<p>Under the agreement, JW Pharmaceutical gains exclusive rights to develop and commercialise bofanglutide in South Korea. Credit: Gan &amp; Lee Pharmaceuticals / PR Newswire.</p>
<div class="lb-trans"><p>根據協議，JW Pharmaceutical 獲得在韓國開發和商業化 bofanglutide 的獨佔權。來源：Gan &amp; Lee Pharmaceuticals / PR Newswire。</p>
</div><p>Gan &amp; Lee Pharmaceuticals has entered an exclusive licence agreement with JW Pharmaceutical for the clinical development, regulatory approval, and commercialisation of bofanglutide injection in South Korea.</p>
<div class="lb-trans"><p>Gan &amp; Lee Pharmaceuticals 與 JW Pharmaceutical 簽署了獨佔許可協議，涉及在韓國進行 bofanglutide 注射的臨牀開發、監管審批和商業化。</p>
</div><p>Bofanglutide is a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) discovered and developed by Gan &amp; Lee.</p>
<div class="lb-trans"><p>Bofanglutide 是由 Gan &amp; Lee 發現和開發的雙週給藥的類胰高血糖素肽-1 受體激動劑 (GLP-1RA)。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>LOA and PTSR Model - (LAI-287 + semaglutide) in Type 2 Diabetes</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - (LAI-287 + semaglutide) 在 2 型糖尿病中的應用</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>LOA and PTSR Model - CT-868 in Obesity</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - CT-868 在肥胖症中的應用</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現高效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>Under the agreement, JW Pharmaceutical gains exclusive rights to develop and commercialise the injection.</p>
<div class="lb-trans"><p>根據協議，JW Pharmaceutical 獲得開發和商業化該注射劑的獨佔權。</p>
</div><p>Gan &amp; Lee will leverage the strengths of JW Pharmaceutical in R&amp;D to establish a commercial presence in South Korea’s metabolic disease market.</p>
<div class="lb-trans"><p>Gan &amp; Lee 將利用 JW Pharmaceutical 在研發方面的優勢，在韓國的代謝疾病市場建立商業存在。</p>
</div><p>Gan &amp; Lee will receive a non-refundable upfront payment of $5m, with milestone payments up to $76.1m, dependent on research, regulatory, and commercialisation targets.</p>
<div class="lb-trans"><p>Gan &amp; Lee 將獲得 500 萬美元的不可退還預付款，以及高達 7610 萬美元的里程碑付款，具體取決於研究、監管和商業化目標。</p>
</div><p>The company will also obtain tiered royalties on net sales, bringing the total potential transaction value to $81.1m, excluding royalties.</p>
<div class="lb-trans"><p>該公司還將獲得淨銷售額的分級版税，使交易的總潛在價值達到 8110 萬美元，不包括版税。</p>
</div><p>This marks the third overseas out-licensing deal for Bofanglutide, after similar agreements in India and Latin America.</p>
<div class="lb-trans"><p>這是 Bofanglutide 的第三個海外授權交易，此前在印度和拉丁美洲也簽署了類似協議。</p>
</div><p>Bofanglutide has entered Phase III clinical research, targeting indications such as obesity/overweight, type 2 diabetes mellitus, and obstructive sleep apnoea.</p>
<div class="lb-trans"><p>Bofanglutide 已進入 III 期臨牀研究，針對肥胖/超重、2 型糖尿病和阻塞性睡眠呼吸暫停等適應症。</p>
</div><p>Data indicate that the injection reduces body weight and blood glucose levels while favourably affecting metabolic parameters, with a safety and tolerability profile similar to other GLP-1RA therapies.</p>
<div class="lb-trans"><p>數據顯示，該注射劑能夠降低體重和血糖水平，同時對代謝參數產生有利影響，其安全性和耐受性與其他 GLP-1RA 療法相似。</p>
</div><p>The bi-weekly dosing schedule minimises the annual number of injections by half compared to the standard once-weekly alternatives.</p>
<div class="lb-trans"><p>雙週給藥的方案將年注射次數減少了一半，相較於標準的每週一次的替代方案。</p>
</div><p>Gan &amp; Lee Pharmaceuticals chief business officer Dr Zhi Li said: “This partnership with JW Pharmaceutical marks another pivotal step in the globalisation strategy for bofanglutide. GLP-1 therapies are reshaping the global treatment landscape for metabolic diseases.</p>
<div class="lb-trans"><p>Gan &amp; Lee Pharmaceuticals 首席商務官 Dr Zhi Li 表示：“與 JW Pharmaceutical 的合作標誌着 bofanglutide 全球化戰略的又一個關鍵步驟。GLP-1 療法正在重塑代謝疾病的全球治療格局。</p>
</div><p>“The convenience of Bofanglutide’s bi-weekly dosing and its compelling clinical benefits will help address the unmet medical needs of South Korean patients. With over 80 years of experience, JW brings deep development and commercial expertise in metabolic diseases—a key factor in our decision to partner with JW.”</p>
<div class="lb-trans"><p>“Bofanglutide 雙週給藥的便利性及其顯著的臨牀益處將有助於滿足韓國患者未被滿足的醫療需求。JW 擁有超過 80 年的經驗，在代謝疾病領域具備深厚的開發和商業專業知識，這是我們選擇與 JW 合作的關鍵因素。”</p>
</div>

甘李藥業與 JW 製藥達成博方魯肽商業化協議